Mineral And Bone Disorder Treatment Global Market Analysis, Trends, Growth, Research And Forecast 2033

The mineral and bone disorder treatment market size has grown strongly in recent years. It will grow from $3.06 billion in 2023 to $3.3 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to chronic kidney disease, aging population, rising awareness of mineral and bone disorders, increased availability of mineral and bone disorder treatments, rising disposable income levels.

The mineral and bone disorder treatment market size is expected to see strong growth in the next few years. It will grow to $4.34 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to rising demand for quality of life treatments, growing demand for personalized medicine, government spending on healthcare, rising awareness of the importance of early diagnosis. Major trends in the forecast period include advancements in medical research, pharmaceutical developments, digital health, biologic therapies, telehealth and remote monitoring.

Market Overview -
Mineral and bone disorder treatment refers to a treatment procedure recommended when there is an imbalance in the levels of calcium and phosphorus in the blood. The treatment regulates the levels of certain minerals and hormones in the blood to prevent bone and blood vessel damage.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=12956&type=smp

Growing Elderly Population Boosts Mineral And Bone Disorder Treatment Market
The increased elderly population is expected to boost the growth of the mineral and bone disorder treatment market going forward. The elderly population is a demographic group defined as individuals who are 65 years old or older. Elderly people experience muscle and bone mass loss, leading to weakness and reduced strength. Mineral and bone treatment can help prevent age-related changes in muscles, bones and joints, strengthen bones and delay the pace of bone loss. For instance, according to a report published by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, by 2030, the number of people aged 60 years or older is expected to increase from 1 billion in 2020 to 1.4 billion and 2.1 billion by 2050. The number of people aged 80 years or older is projected to be three times from 143 million in 2020 to 426 million in 2050. Therefore, the increased elderly population is driving the growth of the mineral and bone disorder treatment market.

Competitive Landscape -
Major players in the mineral and bone disorder treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Eli Lilly And Company, Amgen Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Servier Laboratories Pty Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Zydus Cadila Healthcare Ltd., Alembic Pharmaceuticals Limited, Ajanta Pharma Ltd., Abiogen Pharma Spa, Melinta Therapeutics Inc., Intas Pharmaceuticals Ltd., Radius Health Inc., EffRx Pharmaceuticals SA.

Major Companies Focus On New Product Development To Gain A Competitive Edge
Major companies operating in the mineral and bone disorder treatment market are focusing on developing new products and getting them approved to strengthen their position in the market. Drug approval for mineral and bone is increasing due to the aging population and the increasing prevalence of chronic kidney diseases such as TYMLOS (abaloparatide), which contains the active drug abaloparatide, which is a synthetic (lab-made) form of the human parathyroid hormone. For instance, in December 2022, Radius Health Inc., a US-based biopharmaceutical company, received the approval for TYMLOS (abaloparatide), a parathyroid hormone-related peptide [PTHrP(1-34)] analog for the treatment to increase bone density in men with osteoporosis at high risk of fracture. It works as an anabolic agent for the bone by selectively activating the parathyroid hormone 1 receptor (PTH1R) expressed in osteoblasts and osteocytes, leading to increased bone formation and density.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/mineral-and-bone-disorder-treatment-global-market-report

Key Segments -

The mineral and bone disorder treatment market covered in this report is segmented -

1) By Treatment: Diet; Nutrition; Medication; Supplements; Dialysis
2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
3) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.